User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Evolution of [18F]fluorodeoxyglucose and [18F]fluoroazomycin arabinoside PET uptake distributions in lung tumours during radiation therapy.

Primary tabs

Di Perri, Dario [UCL] Lee, John Aldo [UCL] Bol, Anne [UCL] Hanin, François-Xavier [UCL] Janssens, Guillaume [IBA] Labar, Daniel [UCL] Robert, Annie [UCL] Sterpin, Edmond [UCL] Geets, Xavier [UCL]

(eng) BACKGROUND: Dose painting (DP) aims to improve radiation therapy (RT) outcome by targeting radioresistant tumour regions identified through functional imaging, e.g., positron emission tomography (PET). Importantly, the expected benefit of DP relies on the ability of PET imaging to identify tumour areas which could be consistently targeted throughout the treatment. In this study, we analysed the spatial stability of two potential DP targets in lung cancer patients undergoing RT: the tumour burden surrogate [18F]fluorodeoxyglucose (FDG) and the hypoxia surrogate [18F]fluoroazomycin arabinoside (FAZA). MATERIALS AND METHODS: Thirteen patients with unresectable lung tumours underwent FDG and FAZA 4D-PET/CT before (pre), and during the second (w2) and third (w3) weeks of RT. All PET/CT were reconstructed in their time-averaged midposition (MidP) for further analysis. The metabolic tumour volume (MTV: FDG standardised uptake value (SUV) > 50% SUVmax) and the hypoxic volume (HV: FAZA SUV >1.4) were delineated within the gross tumour volume (GTVCT). The stability of FDG and FAZA PET uptake distributions during RT was subsequently assessed through volume-overlap analysis and voxel-based correlation analysis. RESULTS: The volume-overlap analysis yielded median overlapping fraction (OF) of 0.86 between MTVpre and MTVw2 and 0.82 between MTVpre and MTVw3. In patients with a detectable HV, median OF was 0.82 between HVpre and HVw2 and 0.90 between HVpre and HVw3. The voxel-based correlation analysis yielded median Spearman's correlation coefficient (rS) of 0.87 between FDGpre and FDGw2 and 0.83 between FDGpre and FDGw3. Median rS was 0.78 between FAZApre and FAZAw2 and 0.79 between FAZApre and FAZAw3. CONCLUSIONS: FDG and FAZA PET uptake distributions were spatially stable during the 3 first weeks of RT in patients with unresectable lung cancer, both based on volume- and voxel-based indicators. This might allow for a consistent targeting of high FDG or FAZA PET uptake regions as part of a DP strategy.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2017
Language Anglais
Journal information "Acta Oncologica" - Vol. 56, no. 4, p. 516-524 (2017)
Peer reviewed yes
Publisher Informa Healthcare ((United Kingdom) London)
issn 0284-186X
e-issn 1651-226X
Publication status Publié
Affiliations UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie
UCL - SSS/IREC/EPID - Pôle d'épidémiologie et biostatistique
UCL - (SLuc) Service de radiothérapie oncologique
UCL - (SLuc) Service de médecine nucléaire
Links
  1. Aupérin Anne, Le Péchoux Cecile, Rolland Estelle, Curran Walter J., Furuse Kiyoyuki, Fournel Pierre, Belderbos Jose, Clamon Gerald, Ulutin Hakki Cuneyt, Paulus Rebecca, Yamanaka Takeharu, Bozonnat Marie-Cecile, Uitterhoeve Apollonia, Wang Xiaofei, Stewart Lesley, Arriagada Rodrigo, Burdett Sarah, Pignon Jean-Pierre, Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer, 10.1200/jco.2009.26.2543
  2. Machtay Mitchell, Paulus Rebecca, Moughan Jennifer, Komaki Ritsuko, Bradley J effrey, Choy Hak, Albain Kathy, Movsas Benjamin, Sause William T., Curran Walter J., Defining Local-Regional Control and Its Importance in Locally Advanced Non-small Cell Lung Carcinoma, 10.1097/jto.0b013e3182429682
  3. Machtay Mitchell, Bae Kyounghwa, Movsas Benjamin, Paulus Rebecca, Gore Elizabeth M., Komaki Ritsuko, Albain Kathy, Sause William T., Curran Walter J., Higher Biologically Effective Dose of Radiotherapy Is Associated With Improved Outcomes for Locally Advanced Non–Small Cell Lung Carcinoma Treated With Chemoradiation: An Analysis of the Radiation Therapy Oncology Group, 10.1016/j.ijrobp.2010.09.004
  4. Bradley Jeffrey D, Paulus Rebecca, Komaki Ritsuko, Masters Gregory, Blumenschein George, Schild Steven, Bogart Jeffrey, Hu Chen, Forster Kenneth, Magliocco Anthony, Kavadi Vivek, Garces Yolanda I, Narayan Samir, Iyengar Puneeth, Robinson Cliff, Wynn Raymond B, Koprowski Christopher, Meng Joanne, Beitler Jonathan, Gaur Rakesh, Curran Walter, Choy Hak, Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study, 10.1016/s1470-2045(14)71207-0
  5. Ling C.Clifton, Humm John, Larson Steven, Amols Howard, Fuks Zvi, Leibel Steven, Koutcher Jason A, Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality, 10.1016/s0360-3016(00)00467-3
  6. Piert M, J Nucl Med, 46, 106 (2005)
  7. Abramyuk Andrij, Tokalov Sergey, Zöphel Klaus, Koch Arne, Szluha Lazanyi Kornelia, Gillham Charles, Herrmann Thomas, Abolmaali Nasreddin, Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer?, 10.1016/j.radonc.2009.01.003
  8. Aerts Hugo J.W.L., van Baardwijk Angela A.W., Petit Steven F., Offermann Claudia, Loon Judith van, Houben Ruud, Dingemans Anne-Marie C., Wanders Rinus, Boersma Liesbeth, Borger Jacques, Bootsma Gerben, Geraedts Wiel, Pitz Cordula, Simons Jean, Wouters Bradly G., Oellers Michel, Lambin Philippe, Bosmans Geert, Dekker Andre L.A.J., Ruysscher Dirk De, Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy 18Fluorodeoxyglucose-PET-CT scan, 10.1016/j.radonc.2009.03.006
  9. Aerts Hugo J.W.L., Bussink Johan, Oyen Wim J.G., van Elmpt Wouter, Folgering Annemieke M., Emans Daisy, Velders Marije, Lambin Philippe, De Ruysscher Dirk, Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: A prospective validation, 10.1016/j.lungcan.2011.06.003
  10. Shusharina Nadya, Cho Joseph, Sharp Gregory C., Choi Noah C., Correlation of 18F-FDG Avid Volumes on Pre–Radiation Therapy and Post–Radiation Therapy FDG PET Scans in Recurrent Lung Cancer, 10.1016/j.ijrobp.2014.01.047
  11. Calais J., Thureau S., Dubray B., Modzelewski R., Thiberville L., Gardin I., Vera P., Areas of High 18F-FDG Uptake on Preradiotherapy PET/CT Identify Preferential Sites of Local Relapse After Chemoradiotherapy for Non-Small Cell Lung Cancer, 10.2967/jnumed.114.144253
  12. Gray L. H., Conger A. D., Ebert M., Hornsey S., Scott O. C. A., The Concentration of Oxygen Dissolved in Tissues at the Time of Irradiation as a Factor in Radiotherapy, 10.1259/0007-1285-26-312-638
  13. Aerts Hugo J.W.L., Bosmans Geert, van Baardwijk Angela A.W., Dekker Andre L.A.J., Oellers Michel C., Lambin Philippe, De Ruysscher Dirk, Stability of 18F-Deoxyglucose Uptake Locations Within Tumor During Radiotherapy for NSCLC: A Prospective Study, 10.1016/j.ijrobp.2007.11.049
  14. Bollineni Vikram R., Koole Michel J.B., Pruim Jan, Brouwer Charlotte L., Wiegman Erwin M., Groen Harry J.M., Vlasman Renske, Halmos Gyorgy B., Oosting Sjoukje F., Langendijk Johannes A., Widder Joachim, Steenbakkers Roel J.H.M., Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: Possible implications for radiotherapy treatment planning strategies, 10.1016/j.radonc.2014.10.010
  15. Liu Chi, Pierce II Larry A, Alessio Adam M, Kinahan Paul E, The impact of respiratory motion on tumor quantification and delineation in static PET/CT imaging, 10.1088/0031-9155/54/24/007
  16. Servagi-Vernat Stéphanie, Differding Sarah, Hanin Francois-Xavier, Labar Daniel, Bol Anne, Lee John A., Grégoire Vincent, A prospective clinical study of 18 F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy, 10.1007/s00259-014-2730-x
  17. Goossens Samuel, Senny Frédéric, Lee John Aldo, Janssens Guillaume, Geets Xavier, Assessment of tumor motion reproducibility with audio-visual coaching through successive 4D CT sessions, 10.1120/jacmp.v15i1.4332
  18. Janssens Guillaume, Jacques Laurent, Orban de Xivry Jonathan, Geets Xavier, Macq Benoit, Diffeomorphic Registration of Images with Variable Contrast Enhancement, 10.1155/2011/891585
  19. Wanet Marie, Sterpin Edmond, Janssens Guillaume, Delor Antoine, Lee John Aldo, Geets Xavier, Validation of the mid-position strategy for lung tumors in helical TomoTherapy, 10.1016/j.radonc.2013.10.025
  20. Kruis Matthijs F., van de Kamer Jeroen B., Houweling Antonetta C., Sonke Jan-Jakob, Belderbos José S.A., van Herk Marcel, PET Motion Compensation for Radiation Therapy Using a CT-Based Mid-Position Motion Model: Methodology and Clinical Evaluation, 10.1016/j.ijrobp.2013.06.007
  21. Wolthaus J. W. H., Sonke J.-J., van Herk M., Damen E. M. F., Reconstruction of a time-averaged midposition CT scan for radiotherapy planning of lung cancer patients using deformable registrationa) : Midposition CT reconstruction using deformable registration, 10.1118/1.2966347
  22. van Elmpt Wouter, De Ruysscher Dirk, van der Salm Anke, Lakeman Annemarie, van der Stoep Judith, Emans Daisy, Damen Eugène, Öllers Michel, Sonke Jan-Jakob, Belderbos José, The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer, 10.1016/j.radonc.2012.03.005
  23. Thureau S., Chaumet-Riffaud P., Modzelewski R., Fernandez P., Tessonnier L., Vervueren L., Cachin F., Berriolo-Riedinger A., Olivier P., Kolesnikov-Gauthier H., Blagosklonov O., Bridji B., Devillers A., Collombier L., Courbon F., Gremillet E., Houzard C., Caignon J. M., Roux J., Aide N., Brenot-Rossi I., Doyeux K., Dubray B., Vera P., Interobserver Agreement of Qualitative Analysis and Tumor Delineation of 18F-Fluoromisonidazole and 3'-Deoxy-3'-18F-Fluorothymidine PET Images in Lung Cancer, 10.2967/jnumed.112.118083
  24. Kong Feng-Ming Spring, Frey Kirk A., Quint Leslie E., Haken Randall K. Ten, Hayman James A., Kessler Marc, Chetty Indrin J., Normolle Daniel, Eisbruch Avraham, Lawrence Theodore S., A Pilot Study of [18F]Fluorodeoxyglucose Positron Emission Tomography Scans During and After Radiation-Based Therapy in Patients With Non–Small-Cell Lung Cancer, 10.1200/jco.2006.10.3747
  25. Huang Wei, Zhou Tao, Ma Li, Sun Hongfu, Gong Heyi, Wang Juan, Yu Jinming, Li Baosheng, Standard uptake value and metabolic tumor volume of 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer, 10.1007/s00259-011-1838-5
  26. Vera Pierre, Bohn Pierre, Edet-Sanson Agathe, Salles Alice, Hapdey Sebastien, Gardin Isabelle, Ménard Jean-François, Modzelewski Romain, Thiberville Luc, Dubray Bernard, Simultaneous positron emission tomography (PET) assessment of metabolism with 18F-fluoro-2-deoxy-d-glucose (FDG), proliferation with 18F-fluoro-thymidine (FLT), and hypoxia with 18fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): A pilot study, 10.1016/j.radonc.2010.10.011
  27. Zhang Hua-qi, Yu Jin-ming, Meng Xue, Yue Jin-bo, Feng Rui, Ma Li, Prognostic value of serial [18F]fluorodeoxyglucose PET-CT uptake in stage III patients with non-small cell lung cancer treated by concurrent chemoradiotherapy, 10.1016/j.ejrad.2009.07.023
  28. van Elmpt W., Ollers M., Dingemans A.-M. C., Lambin P., De Ruysscher D., Response Assessment Using 18F-FDG PET Early in the Course of Radiotherapy Correlates with Survival in Advanced-Stage Non-Small Cell Lung Cancer, 10.2967/jnumed.111.102566
  29. Edet-Sanson Agathe, Dubray Bernard, Doyeux Kaya, Back Adeline, Hapdey Sebastien, Modzelewski Romain, Bohn Pierre, Gardin Isabelle, Vera Pierre, Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC), 10.1016/j.radonc.2011.07.023
  30. Usmanij E. A., Geus-Oei L.-F. d., Troost E. G. C., Peters-Bax L., van der Heijden E. H. F. M., Kaanders J. H. A. M., Oyen W. J. G., Schuurbiers O. C. J., Bussink J., 18F-FDG PET Early Response Evaluation of Locally Advanced Non-Small Cell Lung Cancer Treated with Concomitant Chemoradiotherapy, 10.2967/jnumed.112.116921
  31. Lee Chen-Ting, Boss Mary-Keara, Dewhirst Mark W., Imaging Tumor Hypoxia to Advance Radiation Oncology, 10.1089/ars.2013.5759
  32. Withers H. Rodney, The Four R's of Radiotherapy, Advances in Radiation Biology (1975) ISBN:9780120354054 p.241-271, 10.1016/b978-0-12-035405-4.50012-8
  33. Geets X, Quar J Nucl Med Mol Imaging, 57, 271 (2013)
  34. Roels Sarah, Slagmolen Pieter, Nuyts Johan, Lee John A., Loeckx Dirk, Maes Frederik, Stroobants Sigrid, Penninckx Freddy, Haustermans Karin, Biological image-guided radiotherapy in rectal cancer: Is there a role for FMISO or FLT, next to FDG?, 10.1080/02841860802256434
  35. Zschaeck Sebastian, Haase Robert, Abolmaali Nasreddin, Perrin Rosalind, Stützer Kristin, Appold Steffen, Steinbach Jörg, Kotzerke Jörg, Zips Daniel, Richter Christian, Gudziol Volker, Krause Mechthild, Zöphel Klaus, Baumann Michael, Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure, 10.3109/0284186x.2015.1074720
  36. Bittner Martin-Immanuel, Wiedenmann Nicole, Bucher Sabine, Hentschel Michael, Mix Michael, Weber Wolfgang A., Grosu Anca-Ligia, Exploratory geographical analysis of hypoxic subvolumes using 18F-MISO-PET imaging in patients with head and neck cancer in the course of primary chemoradiotherapy, 10.1016/j.radonc.2013.06.012
  37. Mortensen Lise Saksø, Johansen Jørgen, Kallehauge Jesper, Primdahl Hanne, Busk Morten, Lassen Pernille, Alsner Jan, Sørensen Brita S., Toustrup Kasper, Jakobsen Steen, Petersen Jørgen, Petersen Henrik, Theil Jørn, Nordsmark Marianne, Overgaard Jens, FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: Results from the DAHANCA 24 trial, 10.1016/j.radonc.2012.09.015
  38. Bradshaw Tyler J., Yip Stephen, Jallow Ngoneh, Forrest Lisa J., Jeraj Robert, Spatiotemporal Stability of Cu-ATSM and FLT Positron Emission Tomography Distributions During Radiation Therapy, 10.1016/j.ijrobp.2014.02.016
  39. Nyflot Matthew J., Harari Paul M., Yip Stephen, Perlman Scott B., Jeraj Robert, Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx, 10.1016/j.radonc.2012.09.012
  40. Liu H. Helen, Balter Peter, Tutt Teresa, Choi Bum, Zhang Joy, Wang Catherine, Chi Melinda, Luo Dershan, Pan Tinsu, Hunjan Sandeep, Starkschall George, Rosen Isaac, Prado Karl, Liao Zhongxing, Chang Joe, Komaki Ritsuko, Cox James D., Mohan Radhe, Dong Lei, Assessing Respiration-Induced Tumor Motion and Internal Target Volume Using Four-Dimensional Computed Tomography for Radiotherapy of Lung Cancer, 10.1016/j.ijrobp.2006.12.066
  41. Yip Stephen, Chen Aileen B., Aerts Hugo J. W. L., Berbeco Ross, Sensitivity study of voxel-based PET image comparison to image registration algorithms : Sensitivity of PET image comparison to registration algorithms, 10.1118/1.4898125
Bibliographic reference Di Perri, Dario ; Lee, John Aldo ; Bol, Anne ; Hanin, François-Xavier ; Janssens, Guillaume ; et. al. Evolution of [18F]fluorodeoxyglucose and [18F]fluoroazomycin arabinoside PET uptake distributions in lung tumours during radiation therapy.. In: Acta Oncologica, Vol. 56, no. 4, p. 516-524 (2017)
Permanent URL http://hdl.handle.net/2078.1/194126